{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:26:17Z","timestamp":1791379577502,"version":"4.3.3"},"reference-count":23,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Introduction: Drug-assisted interviews have been used in psychiatry for about a century. The use of barbiturates for this purpose has declined, and the use of lorazepam has gained popularity over time for conducting drug-assisted interviews, given a better safety profile. However, the evidence for the use of lorazepam for drugassisted interviews is fragmented and anecdotal, and mostly in the form of case reports. The current review aims to synthesize available evidence on the use of lorazepam-assisted interviews in psychiatry. Methods: For this narrative review, a literature search was conducted using PubMed, Scopus, and Google Scholar. Peer-reviewed articles on the use of lorazepam for drug-assisted interviews for psychiatric patients were identified, and data were manually extracted and synthesized. Results: Eleven case reports and one case series on lorazepam-assisted interviews were identified. Dissociative disorder was the common diagnosis where it was used, with most studies reporting significant improvement after the interviews. Adverse events, though rare, included excessive sedation, disinhibition, agitation, and emotional lability. Interview protocols varied among the studies, with doses ranging from 2 to 18 mg, administered through intravenous routes either as boluses or infusion (rates ranging from 0.05 mg\/min to 0.1 mg\/min). Most studies involved single sessions, with a maximum of 12 sessions in one case report. Conclusion: Lorazepam-assisted interview may hold potential clinical utility in appropriate cases. Future studies are needed to establish efficacy and safety and to evaluate interview protocols. Psychopharmacology Bulletin. 2026;56(1):98\u2013111.<\/jats:p>","DOI":"10.64719\/pb.15429","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:38:16Z","timestamp":1767976696000},"page":"98-111","source":"Crossref","is-referenced-by-count":0,"title":["Lorazepam-Assisted Interview in Clinical Psychiatry: A Narrative Review of Current Evidence and Research Gaps"],"prefix":"10.64719","volume":"56","author":[{"given":"Omar","family":"Afroz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Babu","family":"Ramawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romil","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Gershon A, Shorter E. How amytal changed psychopharmacy: off-label uses of sodium amytal (1920\u201340) Hist Psychiatry. 2019;30(3):352\u2013358. doi: 10.1177\/0957154X19847605.","DOI":"10.1177\/0957154X19847605"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Fackler SM, Anfinson TJ, Rand JA. Serial sodium amytal interviews in the clinical setting. Psychosomatics. 1997;38(6):558\u2013564. doi: 10.1016\/S0033-3182(97)71401-4.","DOI":"10.1016\/S0033-3182(97)71401-4"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lee SS, Park S, Park SS. Use of Lorazepam in drug-assisted interviews: two cases of dissociative amnesia. Psychiatry Investig. 2011;8(4):377\u2013380. doi: 10.4306\/pi.2011.8.4.377.","DOI":"10.4306\/pi.2011.8.4.377"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Stevens CB. Lorazepam in the treatment of acute conversion disorder. Psychiatr Serv. 1990;41(11):1255\u20131257. doi: 10.1176\/ps.41.11.1255.","DOI":"10.1176\/ps.41.11.1255"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Goswami D, Garg H, Carounagarane H, Deb KS. Dexmedetomidine-assisted drug interviews: an observation in psychiatric setting. BMJ Case Rep CP. 2018;11(1):e227195. doi: 10.1136\/bcr-2018-227195.","DOI":"10.1136\/bcr-2018-227195"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Stone J, Hoeritzauer I, Brown K, Carson A. Therapeutic sedation for functional (psychogenic) neurological symptoms. J Psychosom Res. 2014;76(2):165\u2013168. doi: 10.1016\/j.jpsychores.2013.10.003.","DOI":"10.1016\/j.jpsychores.2013.10.003"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sar V. Epidemiology of dissociative disorders: an overview. Epidemiol Res Int. 2011;2011(1):404538. doi: 10.1155\/2011\/404538.","DOI":"10.1155\/2011\/404538"},{"key":"ref8","unstructured":"Peeling JL, Muzio MR. In: StatPearls. StatPearls Publishing; 2025. [Accessed August 27, 2025]. Functional neurologic disorder. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551567\/"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Sahu S, Mishra S, Ranjan Mishra B, Nath S, Mohapatra D. Acute painless visual loss: what the eyes cannot see, the mind should know. Psychiatr Danub. 2021;33(4):591\u2013592. doi: 10.24869\/psyd.2021.591.","DOI":"10.24869\/psyd.2021.591"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Vijayan S, Ramanathan B, Sivakumar P, Selvaraj A. Dissociative fugue \u2013 Unearthing the lost memory with lorazepam-assisted interview. J Psychiatry Spectr. 2025;4(2):186. doi: 10.4103\/jopsys.jopsys_55_24.","DOI":"10.4103\/jopsys.jopsys_55_24"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Seo Y, Shin MH, Kim SG, Kim JH. Effectiveness of lorazepam-assisted interviews in an adolescent with dissociative amnesia: a case report. Neural Regen Res. 2013;8(2):186\u2013190. doi: 10.3969\/j.issn.1673-5374.2013.02.012.","DOI":"10.3969\/j.issn.1673-5374.2013.02.012"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Mushtaq R, Shoib S, Arif T, Shah T, Mushtaq S. First reported case of lorazepam-assisted interview in a young indian female presenting with dissociative identity disorder and improvement in symptoms after the interview. Case Rep Psychiatry. 2014;2014(1):346939. doi: 10.1155\/2014\/346939.","DOI":"10.1155\/2014\/346939"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Maldonado JR. Dissociation. Elsevier. In: Encyclopedia of Stress. 2007:828\u2013837. doi: 10.1016\/B978-012373947-6.00126-4.","DOI":"10.1016\/B978-012373947-6.00126-4"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Poole NA, Wuerz A, Agrawal N. Abreaction for conversion disorder: systematic review with meta-analysis. Br J Psychiatry. 2010;197(2):91\u201395. doi: 10.1192\/bjp.bp.109.066894.","DOI":"10.1192\/bjp.bp.109.066894"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Modak T, Singh S, Kumaran S, Deb KS, Chadda RK. Lorazepam-assisted interview in a resistant case of functional dysphonia. J Voice. 2020;34(5):811.e7\u2013811.e11. doi: 10.1016\/j.jvoice.2019.01.002.","DOI":"10.1016\/j.jvoice.2019.01.002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Ilechukwu STC, Henry T. Amytal interview using intravenous lorazepam in a patient with dissociative fugue. Gen Hosp Psychiatry. 2006;28(6):544\u2013545. doi: 10.1016\/j.genhosppsych.2006.08.001.","DOI":"10.1016\/j.genhosppsych.2006.08.001"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Jiang S, Gunther S, Hartney K, Stern TA. An intravenous lorazepam infusion for dissociative amnesia: a case report. Psychosomatics. 2020;61(6):814\u2013818. doi: 10.1016\/j.psym.2020.01.009.","DOI":"10.1016\/j.psym.2020.01.009"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Gopalakrishnan V, Parameshwaraiah ST, Mallyam V, Shanmugamurthi S, Sannappa AC. Outcome of lorazepam-assisted interview and psychotherapy in a middle-aged female patient with the chronic mixed dissociative disorder: a case report. J Med Sci. 2021;6(3):49\u201350. doi: 10.5005\/jp-journals-10045-00154.","DOI":"10.5005\/jp-journals-10045-00154"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lee LE, Liu CM. Using lorazepam-assisted interview to help with narrative exposure therapy in posttraumatic stress disorder: a case report. Taiwan J Psychiatry. 2021;35(2):101. doi: 10.4103\/tpsy.tpsy_13_21.","DOI":"10.4103\/tpsy.tpsy_13_21"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Edinoff AN, Nix CA, Hollier J et al. Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int. 2021;13(4):594\u2013607. doi: 10.3390\/neurolint13040059.","DOI":"10.3390\/neurolint13040059"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Daurat A, Sagaspe P, Mot\u00e1k L et al. Lorazepam impairs highway driving performance more than heavy alcohol consumption. Accid Anal Prev. 2013;60:31\u201334. doi: 10.1016\/j.aap.2013.08.004.","DOI":"10.1016\/j.aap.2013.08.004"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Vaswani V, Shenoy V, Ifeanyichukwu A. Medicolegal and ethical perspectives in the use of narcoanalysis in criminal investigations in India. Arch Med Health Sci. 2024;12(2):281. doi: 10.4103\/amhs.amhs_17_24.","DOI":"10.4103\/amhs.amhs_17_24"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Reddy B, de Filippis R, Nocera A, Das S. Primary obsessive slowness: a complex presentation and treatment difficulties. Future Pharmacol. 2022;2(2):153\u2013159. doi: 10.3390\/futurepharmacol2020012.","DOI":"10.3390\/futurepharmacol2020012"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:11Z","timestamp":1791315371000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/lorazepam-assisted-interview-in-clinical-psychiatry-a-narrative-review-of-current-evidence-and-research-gaps\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.15429","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}